信达生物(01801.HK)第一季总收入逾24亿人民币 保持40%以上增长

阿斯达克财经
01 May

信达生物(01801.HK) 公布,今年第一季度,共取得总产品收入超过24亿人民币,按年保持40%以上增长。季内,成功上市四款新药,包括肿瘤领域的达伯乐、奥壹新、捷帕力及综合产品线领域的信必敏。

至今,公司已取得15款产品获批上市,3个品种在中国国家药品监督管理局审评中,4个新药分子进入3期或关键性临床研究,另外约15个新药品种已进入临床研究。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-04-30 16:25。)

AASTOCKS新闻

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10